Life Sciences Voice Top Five Newsletter

April 22, 2025

FDA approves Abbott’s latest lab blood test for concussion

March 18, 2023

Alkermes plans to acquire Avadel and its long-acting narcolepsy medication Lumryz for $2.1 billion

October 28, 2025

Must Read

How Healthcare Organizations Are Building AI Centers of Excellence

October 8, 2026

The Rise of Platform Biotech Companies

October 8, 2026

Top 10 Emerging Modalities Beyond RNA Therapeutics

October 8, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Pfizer Reports Phase 3 Results for Litfulo and Phase 2 Atopic Dermatitis Data for Tilrekimig

Mirum’s Brelovitug Meets Main Goal in Phase 3 Chronic Hepatitis Delta Trial

Best-in-disease ambitions are fueled by Roche’s GLP-1/GIP medication’s success in a phase 2 diabetic trial

Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Misses Primary Endpoint

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Merck anticipates a significant win for the $3 billion eye disease opportunity

Novo and Lilly Trade New GLP-1 Data at Major Diabetes Meeting

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

How Healthcare Organizations Are Building AI Centers of Excellence

The Rise of Platform Biotech Companies

Top 10 Emerging Modalities Beyond RNA Therapeutics

Top 10 ESG Priorities for Life Sciences Companies

Insights

Superbugs Could Be the Next Pandemic: We Need a Global, Comprehensive Plan to Address Them Now!

Editor Picks

Life Sciences Voice Top Five Newsletter

FDA approves Abbott’s latest lab blood test for concussion

Alkermes plans to acquire Avadel and its long-acting narcolepsy medication Lumryz for $2.1 billion

Must Read

How Healthcare Organizations Are Building AI Centers of Excellence

The Rise of Platform Biotech Companies

Top 10 Emerging Modalities Beyond RNA Therapeutics

Hot Topics

About Us

Follow Us